As the U.S. Food and Drug Administration’s independent advisers prepare to discuss the full approval of Pfizer’s COVID-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults.